ArticleJournal of diabetes investigation2026
Taiwanese consensus statement on the use of diabetes-specific formula: Scientific evidence.
Article in Journal of diabetes investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionMedical Nutrition Therapy remains the cornerstone of diabetes management. Clinical evidence shows that early intervention with medical nutrition therapy can significantly improve cardiometabolic markers, thereby delaying or preventing diabetes-related complications. As part of medical nutrition therapy, diabetes-specific formula has proven to be an effective tool in clinical practice and a viable support alternative in special circumstances where consuming whole foods is challenging. However, Taiwan currently lacks consensus on diabetes-specific formula products, and many patients with diabetes, as well as some healthcare professionals, still hold misconceptions about these products.
methodsTo address these needs, the Taiwanese Association of Diabetes Educators and the Diabetes Association of the Republic of China, Taiwan, collaborated to form an expert panel to formulate consensus statements on the appropriate use of diabetes-specific formula.
resultsFollowing a comprehensive review of international guidelines and clinical evidence, the panel formulated five consensus statements covering indications, clinical benefits, nutritional composition, and practical applications of diabetes-specific formula.
conclusionThis consensus provides evidence-based recommendations for integrating diabetes-specific formula into individualized diabetes care, particularly in patients with poor glycemic control, malnutrition, sarcopenia, gestational diabetes, or diabetic kidney disease. These statements are tailored to Taiwan's healthcare system but may serve as a reference for other regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.